396 related articles for article (PubMed ID: 25086990)
1. Modified selection criteria for complete cytoreductive surgery plus HIPEC based on peritoneal cancer index and small bowel involvement for peritoneal carcinomatosis of colorectal origin.
Elias D; Mariani A; Cloutier AS; Blot F; Goéré D; Dumont F; Honoré C; Billard V; Dartigues P; Ducreux M
Eur J Surg Oncol; 2014 Nov; 40(11):1467-73. PubMed ID: 25086990
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of visible cardiophrenic angle lymph nodes in the presence of peritoneal metastases from colorectal cancers.
Elias D; Borget I; Farron M; Dromain C; Ducreux M; Goéré D; Honoré C; Boige V; Dumont F; Malka D; Pottier E; Caramella C
Eur J Surg Oncol; 2013 Nov; 39(11):1214-8. PubMed ID: 24044805
[TBL] [Abstract][Full Text] [Related]
3. Cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy treatment of colorectal peritoneal metastases: cohort analysis of high volume disease and cure rate.
Cashin PH; Dranichnikov F; Mahteme H
J Surg Oncol; 2014 Aug; 110(2):203-6. PubMed ID: 24846340
[TBL] [Abstract][Full Text] [Related]
4. Peritoneal carcinomatosis from unusual cancer origins: Is there a role for hyperthermic intraperitoneal chemotherapy?
Honoré C; Goéré D; Macovei R; Colace L; Benhaim L; Elias D
J Visc Surg; 2016 Apr; 153(2):101-7. PubMed ID: 26698380
[TBL] [Abstract][Full Text] [Related]
5. Small bowel involvement is a prognostic factor in colorectal carcinomatosis treated with complete cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy.
Benizri EI; Bernard JL; Rahili A; Benchimol D; Bereder JM
World J Surg Oncol; 2012 Apr; 10():56. PubMed ID: 22494563
[TBL] [Abstract][Full Text] [Related]
6. Survival prognostic factors in patients with colorectal peritoneal carcinomatosis treated with cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy: a single institution experience.
Nikolic S; Dzodic R; Zegarac M; Djurisic I; Gavrilovic D; Vojinovic V; Kocic M; Santrac N; Radlovic P; Radosavljevic D; Pupic G; Martinovic A
J BUON; 2014; 19(1):66-74. PubMed ID: 24659645
[TBL] [Abstract][Full Text] [Related]
7. Peritoneal metastases from colorectal cancer: patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Riss S; Mohamed F; Dayal S; Cecil T; Stift A; Bachleitner-Hofmann T; Moran B
Eur J Surg Oncol; 2013 Sep; 39(9):931-7. PubMed ID: 23810280
[TBL] [Abstract][Full Text] [Related]
8. Patterns of recurrence following complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer.
Braam HJ; van Oudheusden TR; de Hingh IH; Nienhuijs SW; Boerma D; Wiezer MJ; van Ramshorst B
J Surg Oncol; 2014 Jun; 109(8):841-7. PubMed ID: 24619813
[TBL] [Abstract][Full Text] [Related]
9. Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis.
Quenet F; Goéré D; Mehta SS; Roca L; Dumont F; Hessissen M; Saint-Aubert B; Elias D
Ann Surg; 2011 Aug; 254(2):294-301. PubMed ID: 21772129
[TBL] [Abstract][Full Text] [Related]
10. Quality of life after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy: a prospective study of 216 patients.
Passot G; Bakrin N; Roux AS; Vaudoyer D; Gilly FN; Glehen O; Cotte E
Eur J Surg Oncol; 2014 May; 40(5):529-535. PubMed ID: 24370285
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab doubles the early postoperative complication rate after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal origin.
Eveno C; Passot G; Goéré D; Soyer P; Gayat E; Glehen O; Elias D; Pocard M
Ann Surg Oncol; 2014 Jun; 21(6):1792-800. PubMed ID: 24337648
[TBL] [Abstract][Full Text] [Related]
12. Postoperative complications after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy affect long-term outcome of patients with peritoneal metastases from colorectal cancer: a two-center study of 101 patients.
Baratti D; Kusamura S; Iusco D; Bonomi S; Grassi A; Virzì S; Leo E; Deraco M
Dis Colon Rectum; 2014 Jul; 57(7):858-68. PubMed ID: 24901687
[TBL] [Abstract][Full Text] [Related]
13. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for the treatment of endometrial cancer with peritoneal carcinomatosis.
Delotte J; Desantis M; Frigenza M; Quaranta D; Bongain A; Benchimol D; Bereder JM
Eur J Obstet Gynecol Reprod Biol; 2014 Jan; 172():111-4. PubMed ID: 24300558
[TBL] [Abstract][Full Text] [Related]
14. CEA to peritoneal carcinomatosis index (PCI) ratio is prognostic in patients with colorectal cancer peritoneal carcinomatosis undergoing cytoreduction surgery and intraperitoneal chemotherapy: A retrospective cohort study.
Kozman MA; Fisher OM; Rebolledo BJ; Parikh R; Valle SJ; Arrowaili A; Alzahrani N; Liauw W; Morris DL
J Surg Oncol; 2018 Mar; 117(4):725-736. PubMed ID: 29266235
[TBL] [Abstract][Full Text] [Related]
15. Linear Relationship of Peritoneal Cancer Index and Survival in Patients with Peritoneal Metastases from Colorectal Cancer.
Faron M; Macovei R; Goéré D; Honoré C; Benhaim L; Elias D
Ann Surg Oncol; 2016 Jan; 23(1):114-9. PubMed ID: 26014158
[TBL] [Abstract][Full Text] [Related]
16. The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase II clinical study.
Hompes D; D'Hoore A; Van Cutsem E; Fieuws S; Ceelen W; Peeters M; Van der Speeten K; Bertrand C; Legendre H; Kerger J
Ann Surg Oncol; 2012 Jul; 19(7):2186-94. PubMed ID: 22395983
[TBL] [Abstract][Full Text] [Related]
17. Inflammatory bowel disease drastically affects the prognosis of patients treated for peritoneal metastases with combined cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A multicenter study.
Hammoudi N; Eveno C; Lambert J; Maillet M; Glehen O; Goere D; Lourenco N; Allez M; Aparicio T; Pocard M; Gornet JM;
Eur J Surg Oncol; 2018 Jun; 44(6):799-804. PubMed ID: 29650418
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer with peritoneal metastasis.
Lin EK; Hsieh MC; Chen CH; Lu YJ; Wu SY
Medicine (Baltimore); 2016 Dec; 95(52):e5522. PubMed ID: 28033247
[TBL] [Abstract][Full Text] [Related]
19. Patients with colorectal peritoneal metastases and high peritoneal cancer index may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Birgisson H; Enblad M; Artursson S; Ghanipour L; Cashin P; Graf W
Eur J Surg Oncol; 2020 Dec; 46(12):2283-2291. PubMed ID: 32873455
[TBL] [Abstract][Full Text] [Related]
20. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin.
Elias D; Lefevre JH; Chevalier J; Brouquet A; Marchal F; Classe JM; Ferron G; Guilloit JM; Meeus P; Goéré D; Bonastre J
J Clin Oncol; 2009 Feb; 27(5):681-5. PubMed ID: 19103728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
